On June 30, 2025, NeOnc’s Board unanimously approved the company’s participation in the contemplated $50 million equity investment and MENA region expansion under a non-binding term sheet with ...

In other recent news, NeOnc Technologies Holdings Inc. has signed a non-binding term sheet with Quazar Investment for a $50 million equity investment aimed at expanding its clinical trials in the ...

CALABASAS, Calif. - NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biotech company with a current market capitalization of $113.3 million, announced Thursday that its board of ...

CALABASAS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central ...

NeOnc Technologies Holdings, Inc. announced a significant step towards finalizing its strategic investment deal with Quazar Investment, receiving formal approval from its Board of Directors for a ...

NeOnc Technologies Secures Board Approval for $50 Million Strategic Partnership with Quazar Investment Jul. 10, 2025 9:00 AM ET NeOnc Technologies Holdings, Inc. (NTHI) ...

Strategic Capital Raise: Quazar will control and lead a capital formation round of up to $50 million, priced at $25 per share. Use of Proceeds: 70% of the funds will be used to acquire NeOnc ...

Strategic Capital Raise: Quazar will control and lead a capital formation round of up to $50 million, priced at $25 per share. Use of Proceeds: 70% of the funds will be used to acquire NeOnc ...

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform ...

CALABASAS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central ...